EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes [Yahoo! Finance]
Virax Biolabs Group Limited (VRAX)
Company Research
Source: Yahoo! Finance
research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress. "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs. "The launch marks a significant milestone for Virax, as it brings us a step closer to commercializing ViraxImmune as a full in-Vitro Diagnostic product." ImmuneSelect is the company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity. ImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptid
Show less
Read more
Impact Snapshot
Event Time:
VRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRAX alerts
High impacting Virax Biolabs Group Limited news events
Weekly update
A roundup of the hottest topics
VRAX
News
- Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 [Yahoo! Finance]Yahoo! Finance
- Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024PR Newswire
- Virax Biolabs to Participate at ESCMID Global 2024 [Yahoo! Finance]Yahoo! Finance
- Virax Biolabs to Participate at ESCMID Global 2024PR Newswire
- Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency [Yahoo! Finance]Yahoo! Finance
VRAX
Sec Filings
- 4/25/24 - Form 6-K
- 4/16/24 - Form 6-K
- 3/15/24 - Form 6-K
- VRAX's page on the SEC website